A startup founded by David Sinclair has secured $80 million in funding aimed at advancing clinical trials for a new gene therapy focused on anti-aging. This financial boost will facilitate the development and testing of innovative treatments designed to extend longevity.
The funding round was led by significant investors interested in the potential of gene therapy to address aging. The company plans to utilize these resources to conduct rigorous clinical tests that could pave the way for groundbreaking advancements in the field of aging research.
Sinclair, a prominent figure in the scientific community, is known for his work on the biology of aging, and this latest venture may significantly impact future therapeutic options. As the startup moves forward, the clinical trials are expected to be a critical step in demonstrating the efficacy of the proposed therapies.